Morphologic and molecular characteristics of mixed epithelial ovarian cancers

American Journal of Surgical Pathology

Volumn 39, Issue 11, 2015, Pages 1548-1557

  MacKenzie, Robertson ^a   Talhouk, Aline ^c   Eshragh, Sima ^d   Lau, Sherman ^d   Cheung, Daphne ^d   Chow, Christine ^d   Le, Nhu ^b   Cook, Linda S ^e   Wilkinson, Nafisa ^g   McDermott, Jacqueline ^h   Singh, Naveena ^h   Kommoss, Friedrich ⁱ   Pfisterer, Jacobus ^j   Huntsman, David G ^a,c   Köbel, Martin ^f   Kommoss, Stefan ^k   Gilks, Blake ^c,d   Anglesio, Michael S ^c,l  

^a Department of Molecular Oncology ^*  (Canada)

^b Cancer Control Research   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALGARY   (Canada)

^g LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^h BARTS HEALTH NHS TRUST   (United Kingdom)

ⁱ Institute für Pathologie   (Germany)

^j Gynecologic Oncology Center Kiel   (Germany)

^k UNIVERSITY OF TÜBINGEN   (Germany)

^l BRITISH COLUMBIA CANCER AGENCY   (Canada)

more..

Author keywords

Diagnosis; Heterogeneity; Immunohistochemistry; Mixed histology; Ovarian cancer; Ovarian carcinoma

Indexed keywords

TUMOR MARKER;

ADENOCARCINOMA, MUCINOUS; ALBERTA; BIOPSY; BRITISH COLUMBIA; CARCINOMA, ENDOMETRIOID; CHEMISTRY; CLINICAL TRIAL; DNA MUTATIONAL ANALYSIS; EUROPE; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MULTICENTER STUDY; NEOPLASMS, COMPLEX AND MIXED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE;

ADENOCARCINOMA, MUCINOUS; ALBERTA; BIOMARKERS, TUMOR; BIOPSY; BRITISH COLUMBIA; CARCINOMA, ENDOMETRIOID; DNA MUTATIONAL ANALYSIS; EUROPE; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, COMPLEX AND MIXED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHENOTYPE; PREDICTIVE VALUE OF TESTS;

EID: 84944030549     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000476     Document Type: Article

References (48)

1. Auersperg N. The origin of ovarian carcinomas: A unifying hypothesis. Int J Gynecol Pathol. 2011;30:12-21.
2. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5:e232.
3. Kurman RJ, ShihIeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011;42:918-931.
4. Soslow RA. Histologic subtypes of ovarian carcinoma: An overview. Int J Gynecol Pathol. 2008;27:161-174.
5. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221:49-56.
6. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC cancer. 2008;8:17.
7. Gurung A, Hung T, Morin J, et al. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology. 2013;62:59-70.
8. Kalloger SE, Kobel M, Leung S, et al. Calculator for ovarian carcinoma subtype prediction. Mod Pathol. 2011;24:512-521.
9. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor- 1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003;163:2503-2512.
10. Anglesio MS, Kommoss S, Tolcher MC, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013;229:111-120.
11. Gershenson DM, Sun CC, Bodurka D, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecologic oncology. 2009;114:48-52.
12. Tsang YT, Deavers MT, Sun CC, et al. KRAS (but not BRAF) mutations in ovarian serous borderline tumor are associated with recurrent low-grade serous carcinoma. J Pathol. 2013;231:449-456.
13. Carlson JW, Jarboe EA, Kindelberger D, et al. Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications. Int J Gynecol Pathol. 2010;29:310-314.
14. Cuff J, Longacre TA. Endometriosis does not confer improved prognosis in ovarian carcinoma of uniform cell type. Am J Surg Pathol. 2012;36:688-695.
15. Levanon K, Ng V, Piao HY, et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene. 2010;29:1103-1113.
16. Anglesio MS, Carey MS, Kobel M, et al. Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol. 2011;121:407-415.
17. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology. 2001;38:87-95.
18. Prowse AH, Manek S, Varma R, et al. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer. 2006;119:556-562.
19. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363:1532-1543.
20. Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040-1044.
21. Schiavone MB, Herzog TJ, Lewin SN, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205:480 e481-480 e488.
22. Laury AR, Ning G, Quick CM, et al. Fallopian tube correlates of ovarian serous borderline tumors. Am J Surg Pathol. 2011;35: 1759-1765.
23. Li J, Abushahin N, Pang S, et al. Tubal origin of 'ovarian' low-grade serous carcinoma. Mod Pathol. 2011;24:1488-1499.
24. Li J, Fadare O, Xiang L, et al. Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol. 2012;5:8.
25. Kobel M, Kalloger SE, Baker PM, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: A transcanadian study. Am J Surg Pathol. 2010;34:984-993.
26. Han G, Gilks CB, Leung S, et al.Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: An interobserver correlative and immunohistochemical study of 32 cases. Am J Surg Pathol. 2008;32:955-964.
27. Fruscio R, Garbi A, Parma G, et al. Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer. J Ntl Cancer Inst. 2011;103:347-351.
28. Hoskins P, Vergote I, Cervantes A, et al. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Ntl Cancer Inst. 2010;102:1547-1556.
29. Le T, Adolph A, Krepart GV, et al. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol. 2002;85:351-355.
30. Mannel RS, Brady MF, Kohn EC, et al. A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol. 2011;122:89-94.
31. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-1007.
32. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23:41-44.
33. Young RC, Brady MF, Nieberg RK, et al. Adjuvant treatment for early ovarian cancer: A randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin-a gynecologic oncology group study. J Clin Oncol. 2003;21:4350-4355.
34. DeLair D, Han G, Irving JA, et al. HNF-1beta in ovarian carcinomas with serous and clear cell change. Int J Gynecol Pathol. 2013;32:541-546.
35. Gilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 2008;39:1239-1251.
36. Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14:5198-5208.
37. Kobel M, Kalloger SE, Lee S, et al. Biomarker-based ovarian carcinoma typing: A histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidem Biomarkers Prev. 2013;22:1677-1686.
38. Kobel M, Bak J, Bertelsen BI, et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology. 2014;64:1004-1013.
39. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008;26:317-325.
40. Nielsen T, Wallden B, Schaper C, et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffinembedded breast tumor specimens. BMC cancer. 2014;14:177.
41. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39:D945-D950.
42. Kobel M, Bak J, Bertelsen BI, et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology. 2014;64:1004-1013.
43. Mills S, Carter D, Greenson J, et al. Sternberg's Diagnostic Surgical Pathology, 5th ed. Baltimore: Lippincott Williams & Wilkins; 2010.
44. Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO Classification of Tumours of Female Reproductive Organs, 4th ed. Lyon, France: WHO Classification of Tumours; 2014;6.
45. Jiang X, Hitchcock A, Bryan EJ, et al. Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res. 1996;56:3534-3539.
46. Munksgaard PS, Blaakaer J. The association between endometriosis and ovarian cancer: A review of histological, genetic and molecular alterations. Gynecol Oncol. 2012;124:164-169.
47. Sampson JA. Metastatic or embolic endometriosis, due to the menstrual dissemination of endometrial tissue into the venous circulation. Am J Pathol. 1927;3:93-110 143.
48. Anglesio MS, Bashashati A, Wang Y, et al. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. J Pathol. 2015;236:201-209.